ALVR Allovir Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALVR

Price (delayed)

$0.78

Market cap

$89.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.83

Enterprise value

$26.05M

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative ...

Highlights
Allovir's debt has decreased by 22% YoY and by 17% from the previous quarter
ALVR's EPS is up by 17% YoY but it is down by 9% QoQ
The equity has declined by 35% year-on-year and by 25% since the previous quarter
The quick ratio has declined by 32% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.allovir.com
Peers: OMER OMGA

Key stats

What are the main financial stats of ALVR
Market
Shares outstanding
114.87M
Market cap
$89.6M
Enterprise value
$26.05M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.61
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$190.54M
EBITDA
-$182.25M
Free cash flow
-$124.45M
Per share
EPS
-$1.83
Free cash flow per share
-$1.2
Book value per share
$1.28
Revenue per share
$0
TBVPS
$1.83
Balance sheet
Total assets
$190.8M
Total liabilities
$45.02M
Debt
$27.43M
Equity
$145.78M
Working capital
$159.27M
Liquidity
Debt to equity
0.19
Current ratio
6.61
Quick ratio
6.51
Net debt/EBITDA
0.35
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-78.9%
Return on equity
-99.7%
Return on invested capital
-161.2%
Return on capital employed
-117.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALVR stock price

How has the Allovir stock price performed over time
Intraday
-1.27%
1 week
2.63%
1 month
3.65%
1 year
-78.75%
YTD
14.74%
QTD
3.32%

Financial performance

How have Allovir's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$199.9M
Net income
-$190.42M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 17% YoY and by 12% from the previous quarter
The net income is down by 13% year-on-year and by 13% since the previous quarter

Growth

What is Allovir's growth rate over time

Valuation

What is Allovir stock price valuation
P/E
N/A
P/B
0.61
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALVR's EPS is up by 17% YoY but it is down by 9% QoQ
The price to book (P/B) is 53% less than the last 4 quarters average of 1.3
The equity has declined by 35% year-on-year and by 25% since the previous quarter

Efficiency

How efficient is Allovir business performance
Allovir's return on invested capital has decreased by 47% YoY and by 32% QoQ
ALVR's return on equity is down by 24% since the previous quarter and by 22% year-on-year
The return on assets has declined by 23% since the previous quarter and by 17% year-on-year

Dividends

What is ALVR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALVR.

Financial health

How did Allovir financials performed over time
The current ratio has contracted by 34% YoY
The quick ratio has declined by 32% year-on-year
Allovir's debt is 81% less than its equity
The equity has declined by 35% year-on-year and by 25% since the previous quarter
Allovir's debt has decreased by 22% YoY and by 17% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.